F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases
F2G has raised €211M across 5 funding rounds from 18 investors, most recently a round in Aug 2022. Based in Eccles, UK; founded 1998; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-04 | Other | €69M | Advent Life Sciences,Cowen Healthcare Investments,Forbion Capital Partners,Morningside Ventures,Novo Holdings,Sofinnova Partners | View deal → |
| 2020-08-12 | Other | €52M | Cowen Healthcare Investments | View deal → |
| 2016-06-01 | Growth/Late | €55M | Advent Venture Partners,Aisling Capital,Brace Pharma,Merifin Capital,Novartis Venture Fund,Novo A+3 more | View deal → |
| 2012-09-01 | Growth/Late | €27M | Advent Venture Partners,Astellas Venture,K Nominees,Merifin Capital,Novartis Venture Fund,Sunstone Capital | View deal → |
| 2008-08-01 | Early VC | €8.8M | Astellas Venture,BankInvest,K Nominees,Merifin Capital | View deal → |
